United States Drug Patent 8,053,427: Claim Scope, Expiration, Orange Book Relevance, and Generic Entry Risk

U.S. Patent No. 8,053,427 protects specific topical brimonidine gel compositions and methods for treating dermatologic disorders, particularly rosacea-associated erythema. Its strongest protection is directed to a preservative-controlled formulation containing brimonidine, methylparaben, a second preservative, carbomer, polyol, water, and a defined pH. The patent does not broadly cover every topical brimonidine product.

The patent is associated with the Mirvaso-branded brimonidine tartrate gel platform. Its nominal U.S. patent term runs into 2027, subject to any applicable patent-term adjustment, terminal disclaimer, maintenance-fee status, and Orange Book listing history. Brimonidine is a small-molecule drug, so generic rather than biosimilar competition is the relevant pathway.

What does U.S. Patent 8,053,427 protect?

The patent contains two principal composition claim groups and two corresponding method-of-use claim groups.

Claim group	Core subject matter	Relative breadth
Claim 1	Brimonidine, methylparaben, second preservative, carbomer, total polyol, water, pH 4.5-7.5, and a methylparaben/carbomer concentration relationship	Broadest composition claim
Claims 2-6	Dependent limitations covering polyol level, titanium dioxide, carbomer grades, brimonidine tartrate, and preservative identity	Narrower formulation variants
Claim 7	Brimonidine tartrate, methylparaben, second preservative, carbomer, propylene glycol, glycerol, water, and pH 5.0-6.5	Narrower but commercially important composition claim
Claims 8-9	Phenoxyethanol concentration and titanium dioxide limitations	Narrower claim 7 variants
Claims 10-11	Methods using a claim 1 composition to treat or prevent specified skin disorders	Composition-dependent method protection
Claims 12-13	Methods using a claim 7 composition to treat or prevent specified skin disorders	Narrower method protection

The claims use the transition “comprising.” That term generally makes the claims open-ended. A competing formulation can contain additional ingredients and still fall within the claims if it contains every required element and satisfies the concentration and pH limitations.

What are the key limitations of claim 1?

Claim 1 requires all of the following:

Element	Claimed range or requirement
Brimonidine	0.01%-5.0% w/w
Methylparaben	0.05%-0.20% w/w
Second preservative	Required, but not limited by claim 1 to a specific identity
Carbomer	0.80%-1.50% w/w
Total polyol	9.0%-13.0% w/w
Water	Purified water
pH	4.5-7.5
Interaction limitation	If methylparaben exceeds 0.15%, carbomer must be below 1.25%

The final interaction limitation is material. A formulation containing 0.16% methylparaben and 1.25% carbomer would not satisfy the express requirement that carbomer be less than 1.25%. A formulation containing 0.15% methylparaben and 1.25% carbomer does not trigger the conditional limitation because the claim applies only when methylparaben is greater than 0.15%.

A formulation also must contain a second preservative. The claim does not require the second preservative to be one of the five preservatives later listed in claim 6. Claims 1 and 7 should therefore be analyzed separately from the narrower preservative list in claim 6 and claim 8.

How does claim 7 differ from claim 1?

Claim 7 is a more specific composition claim. It requires:

0.1%-0.6% w/w brimonidine tartrate;
0.05%-0.15% w/w methylparaben;
a second preservative selected from sodium benzoate, phenoxyethanol, benzyl alcohol, imidazolidinyl urea, or diazolidinyl urea;
0.80%-1.50% w/w carbomer;
4.5%-6.5% w/w propylene glycol;
4.5%-6.5% w/w glycerol;
purified water; and
pH 5.0-6.5 adjusted with an adequate amount of aqueous sodium hydroxide.

Claim 7 effectively requires propylene glycol and glycerol as separate formulation components. Their combined amount is 9.0%-13.0% w/w, but claim 7 does not use the broader “total polyol” language found in claim 1.

The claim 7 formulation is commercially significant because it maps closely to the type of aqueous gel used for topical brimonidine tartrate products. A generic product may face infringement exposure even if it avoids some optional features in claims 8 and 9.

What formulations are protected by the dependent claims?

Claims 2 and 3: polyol and titanium dioxide

Claim 2 requires approximately 4.5%-6.5% w/w of a first polyol. The term “about” introduces an interpretation issue. Small deviations may be argued to remain within the claim, depending on intrinsic evidence and the prosecution history.

Claim 3 adds 0.04%-0.08% w/w of a water-dispersible form of titanium dioxide. Ordinary titanium dioxide that is not water dispersible may not satisfy this limitation. The physical form and dispersion characteristics can become relevant in an infringement analysis.

Claim 4: specified carbomer grades

Claim 4 limits carbomer to:

carbomer 934P;
carbomer 974P; or
carbomer 980.

A formulation using another carbomer grade may avoid literal infringement of claim 4 while remaining within claim 1 or claim 7 if the broader carbomer limitations are satisfied.

Claim 5: brimonidine tartrate

Claim 5 requires brimonidine tartrate. It does not require a particular particle size, polymorph, hydrate, or salt stoichiometry beyond the claim language.

Claim 6: second preservative

Claim 6 limits the second preservative to sodium benzoate, phenoxyethanol, benzyl alcohol, imidazolidinyl urea, or diazolidinyl urea. A competitor using a different second preservative could avoid claim 6 but may still need to assess claim 1.

Claims 8 and 9: phenoxyethanol and titanium dioxide

Claim 8 requires phenoxyethanol above 0.3% w/w. Claim 9 adds the titanium dioxide limitation from claim 3.

These dependent claims create narrower enforcement positions but also give a challenger more opportunities to avoid infringement by changing preservative concentration or omitting titanium dioxide.

What methods of use are covered?

Claims 10 through 13 are method claims. They require topical administration of a qualifying composition to a skin area that is affected, or prone to be affected, by a skin disorder.

The listed disorders include:

rosacea;
erythema of rosacea;
telangiectasia;
psoriasis;
purpura;
erythema of acne;
eczema;
non-rosacea-related inflammation;
flushing;
skin sagging;
creasing;
wrinkling; and
associated symptoms.

The method claims are not independent of the formulation requirements. A topical product must first meet the composition limitations incorporated from claim 1 or claim 7. A method claim may be difficult to assert against a manufacturer without evidence of intended use, labeling, promotional material, or instructions that encourage the claimed administration.

FDA labeling is relevant because an approved indication for persistent facial erythema associated with rosacea can provide evidence concerning intended use. The FDA-approved Mirvaso label identifies brimonidine tartrate topical gel 0.33% as a topical treatment for persistent facial erythema of rosacea [2].

How strong is the patent estate for brimonidine gel?

The patent’s strongest technical position is the combination of:

brimonidine or brimonidine tartrate;
methylparaben;
a second preservative;
carbomer;
polyol content;
controlled pH; and
a concentration relationship between methylparaben and carbomer.

This combination is more defensible than a claim directed only to brimonidine in a topical gel. The detailed concentration ranges can support a formulation-stability rationale, but they also create multiple design-around paths.

Strengths

Claim 1 covers a broad range of brimonidine concentrations.
Claim 1 does not restrict the second preservative to the five compounds listed in claim 6.
The claims cover both composition and treatment methods.
Claim 7 captures a commercially realistic brimonidine tartrate, propylene glycol, glycerol, and carbomer formulation.
The open-ended “comprising” language permits additional excipients.

Vulnerabilities

The claims depend heavily on quantitative ranges.
A competitor can target concentrations outside one or more claimed intervals.
A different preservative system may avoid dependent claims and potentially claim 1.
A non-carbomer thickener could avoid the carbomer limitation.
A different vehicle with polyol content below 9% or above 13% may avoid claim 1.
Prior-art formulations containing brimonidine, parabens, carbomer, polyols, and conventional preservatives may create anticipation or obviousness arguments.
The method claims may be narrower in practice if the accused product’s label does not encourage the claimed disorders or uses.

When does U.S. Patent 8,053,427 lose exclusivity?

The patent’s nominal term is calculated from the applicable U.S. nonprovisional filing date and is generally 20 years from that date under 35 U.S.C. § 154. Public patent records associate U.S. Patent 8,053,427 with a priority chain reaching back to 2007 and a nominal expiration in 2027 [1].

Event	Date or status
Earliest reported priority	2007
U.S. patent grant	November 8, 2011
Nominal patent term	Into 2027
Regulatory exclusivity	Separate from patent term
Relevant generic pathway	ANDA under the Hatch-Waxman Act
Biosimilar pathway	Not applicable

The exact enforceable expiration date should be determined from the USPTO maintenance-fee record, patent-term calculation, any terminal disclaimer, and any patent-term adjustment. FDA regulatory exclusivity does not extend the patent term. Conversely, patent expiration does not necessarily eliminate other patents that may protect the product, formulation, labeling, or method of use.

What is the Orange Book status of the brimonidine gel patent?

The FDA Orange Book identifies patents submitted by NDA sponsors for approved drug products and lists the associated use codes or product claims where applicable [3]. For Mirvaso, the relevant regulatory product is brimonidine tartrate topical gel 0.33%, approved under NDA 204708.

A patent’s presence in the Orange Book does not itself establish validity or infringement. It affects ANDA certification obligations. A generic applicant may certify that an Orange Book patent is not infringed, is invalid, or is unenforceable under a Paragraph IV certification. The NDA holder may then file an infringement action, generally triggering a potential 30-month stay of approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and FDA treatment of the particular filing [4].

The regulatory analysis should distinguish:

listed product patents;
listed method-of-use patents;
unlisted formulation or manufacturing patents;
patents that have expired;
patents removed from the Orange Book; and
patents that remain enforceable but do not block approval because they are not properly listed.

Which companies are most likely to challenge brimonidine gel exclusivity?

The relevant challengers are generic manufacturers that file ANDAs for brimonidine tartrate topical gel 0.33%. The commercial field can include established dermatology and generic manufacturers, contract-development companies, and vertically integrated drugmakers.

The principal legal mechanism is a Paragraph IV certification. A challenger may argue that:

the proposed formulation does not contain methylparaben;
the proposed carbomer concentration is outside the claimed range;
the polyol concentration is outside the claimed range;
the pH is outside the claimed range;
the product uses a different preservative;
the proposed product does not contain propylene glycol and glycerol in the claimed ranges;
the claims are anticipated by prior art; or
the claims would have been obvious to a skilled formulator.

A Paragraph IV filing does not mean the generic will launch immediately. Litigation, a 30-month stay, a settlement, a judgment, or a pediatric-exclusivity issue can alter the timeline.

What generic launch scenarios exist?

Scenario	Commercial effect
Patent expires without successful enforcement	FDA may approve and the generic can launch after all regulatory requirements are met
Paragraph IV certification with no timely suit	Approval may proceed after the statutory period
Paragraph IV certification followed by litigation	Approval may be stayed for up to the statutory period, subject to court and FDA actions
Paragraph III certification	Approval is deferred until the patent expiration date
Non-infringing formulation	Generic may launch after approval if no other blocking patent or exclusivity remains
Settlement agreement	Launch date may be earlier than patent expiration but depends on the agreement and antitrust constraints
Formulation redesign	Generic may avoid the patent but incur development, stability, and regulatory costs

Because claim 7 is formulation-specific, a generic developer can pursue a design-around strategy rather than challenge every claim. That strategy may involve eliminating methylparaben, using another gelling polymer, changing the polyol system, or adjusting the preservative and pH profile. Each change can affect viscosity, stability, microbial protection, skin tolerability, and bioequivalence.

Are biosimilar risks relevant?

No. Brimonidine tartrate is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an ANDA for a generic drug under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The principal barriers are formulation equivalence, product quality, preservative performance, stability, topical bioequivalence, patent certifications, and possible litigation.

What manufacturing and intellectual-property barriers remain?

The formulation claims create practical manufacturing constraints beyond the literal claim language. A generic developer must control:

brimonidine tartrate assay and uniformity;
carbomer hydration and neutralization;
viscosity across the product shelf life;
pH after sodium hydroxide adjustment;
preservative concentration and antimicrobial effectiveness;
polyol content;
titanium dioxide dispersion, if used;
microbial limits;
container compatibility; and
topical product sameness or bioequivalence.

A formulation that avoids the patent may still require a new stability package and additional clinical or comparative characterization. The patent therefore has commercial value even where its literal scope can be designed around.

How does U.S. Patent 8,053,427 compare with a typical generic brimonidine product?

Issue	Patent-protected formulation	Potential generic design-around
Active ingredient	Brimonidine or brimonidine tartrate	Same active ingredient generally required for ANDA
Thickener	Carbomer	Alternative polymer or different concentration
Preservative	Methylparaben plus second preservative in key claims	Different preservative system
Polyols	9%-13% total in claim 1; propylene glycol and glycerol in claim 7	Different humectants or out-of-range levels
pH	4.5-7.5 in claim 1; 5.0-6.5 in claim 7	pH outside a claimed range, if technically acceptable
Titanium dioxide	Optional in claims 3 and 9	Omit or use a nonqualifying form
Use	Rosacea and other listed disorders	Label limited to nonclaimed uses, subject to induced-infringement risk
Regulatory route	NDA-originator product	ANDA generic pathway

Key Takeaways

U.S. Patent 8,053,427 is a formulation and method patent for topical brimonidine gels.
Claim 1 is the principal broad composition claim, but it requires a specific preservative, carbomer, polyol, water, pH, and concentration relationship.
Claim 7 is narrower and focuses on brimonidine tartrate with propylene glycol, glycerol, carbomer, methylparaben, a listed second preservative, and pH 5.0-6.5.
Claims 10-13 extend protection to topical treatment of rosacea and multiple other skin disorders.
The patent’s nominal expiration is in 2027, subject to the official USPTO term calculation and maintenance status.
Generic, not biosimilar, competition is the relevant threat.
The most credible generic strategy is formulation design-around combined with Paragraph IV or Paragraph III certification, depending on the Orange Book record.
The patent has meaningful formulation value but is vulnerable to concentration, preservative, polymer, polyol, and pH-based design-around strategies.
Other Mirvaso-related patents, listed use patents, regulatory exclusivity, and settlement agreements must be assessed separately before determining an actual launch date.

Frequently Asked Questions

Is U.S. Patent 8,053,427 limited to rosacea?

No. The composition claims are not limited to rosacea. The method claims list rosacea and several other skin disorders, including erythema, telangiectasia, psoriasis, acne-related erythema, eczema, flushing, and wrinkling-related symptoms.

Does a generic need to use methylparaben to infringe?

Not necessarily. Claim 1 requires methylparaben, while claim 7 also requires methylparaben. A generic using a different preservative may avoid literal infringement of these claims, although other patents or an equivalents theory may remain relevant.

Can a product with 1.25% carbomer and 0.16% methylparaben infringe claim 1?

On the face of the claim language, it would not satisfy claim 1 because carbomer must be less than 1.25% when methylparaben is greater than 0.15%. The complete claim construction and any equivalents analysis would require the patent record and accused formulation data.

Does FDA approval of a generic prove that the patent is invalid?

No. FDA approval and patent validity are separate issues. A generic may receive approval subject to patent certifications and statutory timing rules, while infringement or validity litigation proceeds independently.

Is titanium dioxide required in the commercial product?

No. Titanium dioxide is required only by dependent claims 3 and 9. It is not required by independent claims 1 or 7.

References

United States Patent and Trademark Office. (2011). U.S. Patent No. 8,053,427, topical formulations of brimonidine. USPTO Patent Center and Patent Assignment records.
U.S. Food and Drug Administration. (2013). Mirvaso (brimonidine tartrate) topical gel, 0.33%: Prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certification requirements under the Hatch-Waxman Amendments. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	083651	⤷ Start Trial
Australia	2011317554	⤷ Start Trial
Brazil	112013009578	⤷ Start Trial
Canada	2814952	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,053,427

Which drugs does patent 8,053,427 protect, and when does it expire?

Summary for Patent: 8,053,427